APYX - Apyx stock rises on FDA clearance of Renuvion APR Handpiece
2023-04-28 08:15:57 ET
- The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Apyx Medical's ( NASDAQ: APYX ) Renuvion APR Handpiece for coagulation of subcutaneous soft tissues after liposuction for aesthetic body contouring.
- "The Renuvion APR handpiece is the only device to have a 510(k) clearance for use following liposuction," said Charlie Goodwin, Apyx's president and CEO.
- Goodwin noted that the company now has the required 510(k) clearances to resolve the remaining limitations of the FDA Safety Communication.
- APYX +7.62% to $3.25 premarket April 28
For further details see:
Apyx stock rises on FDA clearance of Renuvion APR Handpiece